Journal
VIRUSES-BASEL
Volume 13, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/v13040667
Keywords
broad-spectrum antivirals; lethal mutagenesis; chain terminator; nucleoside analogues
Categories
Ask authors/readers for more resources
The emergence or re-emergence of viruses with epidemic and pandemic potential poses significant human health threats, and although vaccines are key in controlling virus spread, their development may face obstacles such as safety concerns. Developing broad-spectrum antiviral molecules, particularly nucleoside analogues, for a fast response in emergency situations is crucial in combating outbreak crises.
The emergence or re-emergence of viruses with epidemic and/or pandemic potential, such as Ebola, Zika, Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus 1 and 2 (SARS and SARS-CoV-2) viruses, or new strains of influenza represents significant human health threats due to the absence of available treatments. Vaccines represent a key answer to control these viruses. However, in the case of a public health emergency, vaccine development, safety, and partial efficacy concerns may hinder their prompt deployment. Thus, developing broad-spectrum antiviral molecules for a fast response is essential to face an outbreak crisis as well as for bioweapon countermeasures. So far, broad-spectrum antivirals include two main categories: the family of drugs targeting the host-cell machinery essential for virus infection and replication, and the family of drugs directly targeting viruses. Among the molecules directly targeting viruses, nucleoside analogues form an essential class of broad-spectrum antiviral drugs. In this review, we will discuss the interest for broad-spectrum antiviral strategies and their limitations, with an emphasis on virus-targeted, broad-spectrum, antiviral nucleoside analogues and their mechanisms of action.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available